These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 26620373

  • 1. Docosahexaenoic Acid Attenuates Cardiovascular Risk Factors via a Decline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Plasma Levels.
    Rodríguez-Pérez C, Ramprasath VR, Pu S, Sabra A, Quirantes-Piné R, Segura-Carretero A, Jones PJ.
    Lipids; 2016 Jan; 51(1):75-83. PubMed ID: 26620373
    [Abstract] [Full Text] [Related]

  • 2. Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial.
    Pu S, Rodríguez-Pérez C, Ramprasath VR, Segura-Carretero A, Jones PJ.
    Vascul Pharmacol; 2016 Dec; 87():60-65. PubMed ID: 27374222
    [Abstract] [Full Text] [Related]

  • 3. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P, Stenman UH, Gylling H.
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [Abstract] [Full Text] [Related]

  • 4. DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial.
    Jones PJ, Senanayake VK, Pu S, Jenkins DJ, Connelly PW, Lamarche B, Couture P, Charest A, Baril-Gravel L, West SG, Liu X, Fleming JA, McCrea CE, Kris-Etherton PM.
    Am J Clin Nutr; 2014 Jul; 100(1):88-97. PubMed ID: 24829493
    [Abstract] [Full Text] [Related]

  • 5. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J.
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [Abstract] [Full Text] [Related]

  • 6. Docosahexaenoic acid-enriched canola oil increases adiponectin concentrations: a randomized crossover controlled intervention trial.
    Baril-Gravel L, Labonté ME, Couture P, Vohl MC, Charest A, Guay V, Jenkins DA, Connelly PW, West S, Kris-Etherton PM, Jones PJ, Fleming JA, Lamarche B.
    Nutr Metab Cardiovasc Dis; 2015 Jan; 25(1):52-9. PubMed ID: 25240692
    [Abstract] [Full Text] [Related]

  • 7. High-oleic canola oil consumption enriches LDL particle cholesteryl oleate content and reduces LDL proteoglycan binding in humans.
    Jones PJ, MacKay DS, Senanayake VK, Pu S, Jenkins DJ, Connelly PW, Lamarche B, Couture P, Kris-Etherton PM, West SG, Liu X, Fleming JA, Hantgan RR, Rudel LL.
    Atherosclerosis; 2015 Feb; 238(2):231-8. PubMed ID: 25528432
    [Abstract] [Full Text] [Related]

  • 8. Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre- and postmenopausal women: A randomised study.
    Graversen CB, Lundbye-Christensen S, Thomsen B, Christensen JH, Schmidt EB.
    Vascul Pharmacol; 2016 Jan; 76():37-41. PubMed ID: 26143741
    [Abstract] [Full Text] [Related]

  • 9. Interactions between dietary oil treatments and genetic variants modulate fatty acid ethanolamides in plasma and body weight composition.
    Pu S, Eck P, Jenkins DJ, Connelly PW, Lamarche B, Kris-Etherton PM, West SG, Liu X, Jones PJ.
    Br J Nutr; 2016 Mar 28; 115(6):1012-23. PubMed ID: 26806592
    [Abstract] [Full Text] [Related]

  • 10. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, Verma S.
    Arterioscler Thromb Vasc Biol; 2015 Oct 28; 35(10):2254-9. PubMed ID: 26293463
    [Abstract] [Full Text] [Related]

  • 11. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.
    Persson L, Cao G, Ståhle L, Sjöberg BG, Troutt JS, Konrad RJ, Gälman C, Wallén H, Eriksson M, Hafström I, Lind S, Dahlin M, Amark P, Angelin B, Rudling M.
    Arterioscler Thromb Vasc Biol; 2010 Dec 28; 30(12):2666-72. PubMed ID: 20884874
    [Abstract] [Full Text] [Related]

  • 12. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 28; 25(4):411-7. PubMed ID: 25466598
    [Abstract] [Full Text] [Related]

  • 13. Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2.
    Brouwers MC, van Greevenbroek MM, Konrad RJ, Troutt JS, Schaper NC, Stehouwer CD.
    Clin Sci (Lond); 2014 May 28; 126(9):679-84. PubMed ID: 24308640
    [Abstract] [Full Text] [Related]

  • 14. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan 28; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

  • 15. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M, Plana N, Ibarretxe D, Cabré A, González M, Ribalta J, Masana L.
    Clin Sci (Lond); 2015 Jun 28; 128(12):877-82. PubMed ID: 25649668
    [Abstract] [Full Text] [Related]

  • 16. Plasma fatty acid changes following consumption of dietary oils containing n-3, n-6, and n-9 fatty acids at different proportions: preliminary findings of the Canola Oil Multicenter Intervention Trial (COMIT).
    Senanayake VK, Pu S, Jenkins DA, Lamarche B, Kris-Etherton PM, West SG, Fleming JA, Liu X, McCrea CE, Jones PJ.
    Trials; 2014 Apr 23; 15():136. PubMed ID: 24754911
    [Abstract] [Full Text] [Related]

  • 17. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 23; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

  • 18. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N.
    J Diabetes Complications; 2015 Aug 23; 29(8):1165-70. PubMed ID: 26412029
    [Abstract] [Full Text] [Related]

  • 19. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K, Park BS, Kim YW, Vaziri ND.
    Am J Kidney Dis; 2014 Apr 23; 63(4):584-9. PubMed ID: 24315769
    [Abstract] [Full Text] [Related]

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.
    Hepatology; 2008 Aug 23; 48(2):646-54. PubMed ID: 18666258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.